Back to Search Start Over

Building a vertically integrated genomic learning health system: The biobank at the Colorado Center for Personalized Medicine.

Authors :
Wiley LK
Shortt JA
Roberts ER
Lowery J
Kudron E
Lin M
Mayer D
Wilson M
Brunetti TM
Chavan S
Phang TL
Pozdeyev N
Lesny J
Wicks SJ
Moore ET
Morgenstern JL
Roff AN
Shalowitz EL
Stewart A
Williams C
Edelmann MN
Hull M
Patton JT
Axell L
Ku L
Lee YM
Jirikowic J
Tanaka A
Todd E
White S
Peterson B
Hearst E
Zane R
Greene CS
Mathias R
Coors M
Taylor M
Ghosh D
Kahn MG
Brooks IM
Aquilante CL
Kao D
Rafaels N
Crooks KR
Hess S
Barnes KC
Gignoux CR
Source :
American journal of human genetics [Am J Hum Genet] 2024 Jan 04; Vol. 111 (1), pp. 11-23.
Publication Year :
2024

Abstract

Precision medicine initiatives across the globe have led to a revolution of repositories linking large-scale genomic data with electronic health records, enabling genomic analyses across the entire phenome. Many of these initiatives focus solely on research insights, leading to limited direct benefit to patients. We describe the biobank at the Colorado Center for Personalized Medicine (CCPM Biobank) that was jointly developed by the University of Colorado Anschutz Medical Campus and UCHealth to serve as a unique, dual-purpose research and clinical resource accelerating personalized medicine. This living resource currently has more than 200,000 participants with ongoing recruitment. We highlight the clinical, laboratory, regulatory, and HIPAA-compliant informatics infrastructure along with our stakeholder engagement, consent, recontact, and participant engagement strategies. We characterize aspects of genetic and geographic diversity unique to the Rocky Mountain region, the primary catchment area for CCPM Biobank participants. We leverage linked health and demographic information of the CCPM Biobank participant population to demonstrate the utility of the CCPM Biobank to replicate complex trait associations in the first 33,674 genotyped individuals across multiple disease domains. Finally, we describe our current efforts toward return of clinical genetic test results, including high-impact pathogenic variants and pharmacogenetic information, and our broader goals as the CCPM Biobank continues to grow. Bringing clinical and research interests together fosters unique clinical and translational questions that can be addressed from the large EHR-linked CCPM Biobank resource within a HIPAA- and CLIA-certified environment.<br />Competing Interests: Declaration of interests K.C.B. owns stock in Tempus and Galatea Bio and is an employee of Oxford Nanopore Technologies. C.R.G. owns stock in 23andMe, Inc.<br /> (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1537-6605
Volume :
111
Issue :
1
Database :
MEDLINE
Journal :
American journal of human genetics
Publication Type :
Academic Journal
Accession number :
38181729
Full Text :
https://doi.org/10.1016/j.ajhg.2023.12.001